[3H]WAY–100635 for 5–HT1A receptor autoradiography in human brain: a comparison with [3H]8–OH–DPAT and demonstration of increased binding in the frontal cortex in schizophrenia

WAY-100635 is the first selective, silent 5-HT1A (5-hydroxytryptamine1A, serotonin-1A) receptor antagonist. We have investigated the use of [3H]WAY-100635 as a quantitative autoradiographic ligand in post-mortem human hippocampus, raphe and four cortical regions, and compared it with the 5-HT1A receptor agonist, [3H]8-OH-DPAT. Saturation studies showed an average Kd for [3H]WAY-100635 binding in hippocampus of 1.1 nM. The regional and laminar distributions of [3H]WAY-100635 binding and [3H]8-OH-DPAT binding were similar. The density of [3H]WAY-100635 binding sites was 60-70% more than that of [3H]8-OH-DPAT in all areas examined except the cingulate gyrus where it was 165% higher. [3H]WAY-100635 binding was robust and was not affected by the post-mortem interval, freezer storage time or brain pH (agonal state). Using [3H]WAY-100635, we confirmed an increase of 5-HT1A receptor binding sites in the frontal cortex in schizophrenia, previously demonstrated with [3H]8-OH-DPAT. Compared to [3H]8-OH-DPAT, [3H]WAY-100635 has two advantages: it has a higher selectivity and affinity for the 5-HT1A receptor, and it recognizes 5-HT1A receptors whether or not they are coupled to a G-protein, whereas [3H]8-OH-DPAT primarily detects coupled receptors. Given these considerations, the [3H]WAY-100635 binding data in schizophrenia clarify two points. First, they indicate that the elevated [3H]8-OH-DPAT binding seen in the same cases is attributable to an increase of 5-HT1A receptors rather than any other binding site. Second, the enhanced [3H]8-OH-DPAT binding in schizophrenia reflects an increased density of 5-HT1A receptors, not an increased percentage of 5-HT1A receptors which are G-protein-coupled. We conclude that [3H]WAY-100635 is a valuable autoradiographic ligand for the qualitative and quantitative study of 5-HT1A receptors in the human brain.

[1]  M. Hamon,et al.  Pharmacological and Physicochemical Properties of Pre‐Versus Postsynaptic 5‐Hydroxytryptamine1A Receptor Binding Sites in the Rat Brain: A Quantitative Autoradiographic Study , 1992, Journal of neurochemistry.

[2]  J. Glowinski,et al.  Identification of presynaptic serotonin autoreceptors using a new ligand: 3H-PAT , 1983, Nature.

[3]  M. Hamon,et al.  Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.

[4]  Altered G-protein coupling of a frontal cortical low affinity [3H]8-hydroxy-N,N-dipropyl-2-aminotetralin serotonergic binding site in Alzheimer's disease , 1995, Behavioural Brain Research.

[5]  G. Aghajanian,et al.  Responses of hippocampal pyramidal cells to putative serotonin 5-HT1A and 5-HT1B agonists: A comparative study with dorsal raphe neurons , 1988, Neuropharmacology.

[6]  M. Martres,et al.  Chronic alcoholization alters the expression of 5-HT1A and 5-HT1B receptor subtypes in rat brain. , 1995, European journal of pharmacology.

[7]  M. Erlander,et al.  A novel adenylyl cyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms , 1993, Neuron.

[8]  Paul J. Harrison,et al.  The effects of clozapine and haloperidol on serotonin-1A, -2A and -2C receptor gene expression and serotonin metabolism in the rat forebrain , 1996, Neuroscience.

[9]  D L Rosene,et al.  Cingulate cortex of the rhesus monkey: I. Cytoarchitecture and thalamic afferents , 1987, The Journal of comparative neurology.

[10]  J. Deakin,et al.  Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT1A receptors in ventral prefrontal cortex in schizophrenia , 1996, Biological Psychiatry.

[11]  Allan Fletcher,et al.  Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist , 1995, Behavioural Brain Research.

[12]  M. Hamon,et al.  Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins. , 1990, Biochemical pharmacology.

[13]  M. Hamon,et al.  [3H]8‐Hydroxy‐2‐(Di‐n‐Propylamino)Tetralin Binding to Pre‐ and Postsynaptic 5‐Hydroxytryptamine Sites in Various Regions of the Rat Brain , 1985, Journal of neurochemistry.

[14]  Anat Biegon,et al.  Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: effects of age and alcohol , 1991, Brain Research.

[15]  Rémi Quirion,et al.  Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus , 1992, Brain Research.

[16]  Paul J. Harrison,et al.  The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins , 1995, Neuroscience Letters.

[17]  E. Azmitia,et al.  Cellular Localization of the 5-HT1A Receptor in Primate Brain Neurons and Glial Cells , 1996, Neuropsychopharmacology.

[18]  Paul J. Harrison,et al.  The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain , 1995, Brain Research.

[19]  Paul J. Harrison,et al.  Detection and quantitation of 5-HT1A and 5-HT2A receptor mRNAs in human hippocampus using a reverse transcriptase-polymerase chain reaction (RT-PCR) technique and their correlation with binding site densities and age , 1994, Neuroscience Letters.

[20]  M. Minchin,et al.  Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.

[21]  X. Khawaja,et al.  Quantitative autoradiographic characterisation of the binding of [3H]WAY-100635, a selective 5-HT1A receptor antagonist , 1995, Brain Research.

[22]  A A Lammertsma,et al.  Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.

[23]  S. Beck,et al.  Comparison of 5-hydroxytryptamine1A-mediated hyperpolarization in CA1 and CA3 hippocampal pyramidal cells. , 1992, The Journal of pharmacology and experimental therapeutics.

[24]  Paul J. Harrison,et al.  5-HT1A and 5-HT2A Receptor mRNAs and Binding Site Densities Are Differentially Altered in Schizophrenia , 1996, Neuropsychopharmacology.

[25]  J. Palacios,et al.  Serotonin receptors in the human brain—IV. Autoradiographic mapping of serotonin-2 receptors , 1987, Neuroscience.

[26]  T. Reader,et al.  Heterogeneity of Cortical and Hippocampal 5‐HT1A Receptors: A Reappraisal of Homogenate Binding with 8‐[3H]Hydroxydipropylaminotetralin , 1994, Journal of neurochemistry.

[27]  B. Kobilka,et al.  Adrenergic receptors as models for G protein-coupled receptors. , 1992, Annual review of neuroscience.

[28]  P A Sargent,et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.

[29]  H. Meltzer,et al.  Serotonin1A receptors are increased in postmortem prefrontal cortex in schizophrenia , 1996, Brain Research.

[30]  M. Goldstein,et al.  Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists. , 1990, Molecular pharmacology.

[31]  I A Cliffe,et al.  A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.

[32]  S. Peroutka,et al.  Molecular biology of serotonin (5‐HT) receptors , 1994, Synapse.

[33]  M. Cullen,et al.  Characterization of High‐Affinity Dopamine D2 Receptors and Modulation of Affinity States by Guanine Nucleotides in Cholate‐Solubilized Bovine Striatal Preparations , 1986, Journal of neurochemistry.

[34]  M. Hamon,et al.  The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. , 1995, European journal of pharmacology.

[35]  C. Tanaka,et al.  Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. , 1991, Life sciences.

[36]  S. Ross,et al.  Different effects on the responses of functional pre- and postsynaptic 5-HT1A receptors by repeated treatment of rats with the 5-HT1A receptor agonist 8-OH-DPAT , 1990, Neuropharmacology.

[37]  B. Winblad,et al.  Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer's disease , 1991, Neuroscience Letters.

[38]  Mustapha Riad,et al.  Immunocytochemical localization of serotonin1A receptors in the rat central nervous system , 1996, The Journal of comparative neurology.